First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Yaël C. Cohen, Hila Magen, Daniel Morillo et al.|Journal of Clinical Oncology|2023Cited by 88
S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)María‐Victoria Mateos, Hila Magen, Moshe E. Gatt et al.|HemaSphere|2023Cited by 9
POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)Yaël C. Cohen, Hila Magen, Daniel Morillo et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 1
CT-1498: A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)Krish Patel, Matthew Ku, Joanna Rhodes et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1
MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)Yaël C. Cohen, Hila Magen, Daniel Morillo et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 1